Podcasts about Exploratory

For our 50th episode of GeOCHemISTea, we're doing something a little different... a panel discussion that brings together two very different perspectives on one deceptively simple problem: levelling geochemical data. Joined by a government survey geochemist, Pedro Acosta-Gongora, and a mathematical geologist, Tom Carmichael, this conversation digs into what levelling really means in practice, why it's become standard in regional datasets, and where it can quietly distort the geological signal. From legacy data and batch effects to the tension between clean maps and real-world noise, this episode explores the intersection of applied geochemistry and data science.If you've ever worked with multiple datasets and wondered “can I actually trust this?...” this panel is for you.For this episode we read:Exploratory data analysis of geochemical exploration data (Arne and Garrett, 2026)Data Leveling of Multi-Map Geochemical Exploration Data Using Compositional Data Analysis: A Case Study from the Baiyinchagan-Maodeng Area, Inner Mongolia, China (Tang et al., 2025)Levelling of multi-generational and spatialyy isolated geochemical surveys (Main and Champion, 2022)G-BASE data conditioning procedures fro stream sediment and soil chemical analyses (Lister and Johnson, 2005)

"Registered reports foster clarity upfront…"Dr. Oscar Esteban is a professor at Lausanne University Hospital whose lab develops open neuroimaging infrastructure, best known for tools like fMRIPrep and MRIQC. Dr. Mallar Chakravarty is Director of the Brain Imaging Center at the Douglas Research Centre at McGill University and co-editor-in-chief of Aperture Neuro.In this conversation, Peter, Mallar, and Oscar unpack what registered reports are and why they emerged as a response to the file drawer problem and publication bias toward positive results. Drawing on Oscar's firsthand experience using registered reports in his own lab, the discussion explores how front-loading peer review can sharpen experimental design, protect researchers pursuing high-risk science, and give trainees meaningful early career credit. But the conversation doesn't shy away from harder questions: Can any publication mechanism truly fix an incentive-driven culture? Where does the natural, iterative cycle of exploratory science fit in? And are registered reports the right tool for every type of science or just some of it?We hope you enjoy this episode!Chapters:06:12 - Understanding Registered Reports10:48 - The Origin and Motivation Behind Registered Reports15:03 - Concerns and Challenges of Registered Reports21:08 - Exploratory vs. Confirmatory Research30:50 - The Role of Registered Reports in Training Researchers42:15 - The Role of Pre-registration in Scientific Rigor53:59 - The Systemic Challenges in Scientific Publishing01:06:29 - Concluding Thoughts on Registered ReportsResources:01:02:37 - About PCI Registered Reports - Peer Community In https://rr.peercommunityin.org/aboutEpisode producers:Xuqian Michelle Li

In this episode, we continue the play series by talking about the gentle bridge from exploratory play into functional play. If a child loves dumping toys, spinning wheels, dropping objects, or lining things up, it can be tempting to rush toward "using the toy the right way." But functional play grows best when it feels safe, connected, and joyful. This episode explores how to support the shift from sensory-driven exploratory play into one-step and early multi-step functional play without turning it into a power struggle. Instead of forcing imitation or moving too quickly into adult-led teaching, we'll walk through how to build from what the child already loves by using regulation, connection, and one small expansion at a time. This conversation is especially helpful for educators, therapists, and caregivers supporting autistic children who are ready for the next layer of play but still need the sensory and emotional safety of familiar patterns. In This Episode, You'll Learn • What functional play looks like in practical, classroom-friendly terms • Why cause and effect is often the first bridge out of exploratory play • Why rushing the shift into functional play can create stress and resistance • The simple framework: Regulate → Connect → Expand • How to expand dumping, spinning, and "put in" play patterns • Readiness signs that tell you a child may be ready for one-step play • Why building multiple one-step actions makes pretend play easier later • How to keep functional play playful instead of turning it into drill work • Why goals should guide exposure rather than create performance pressure • How small expansions support long-term sequencing and symbolic play Key Takeaways • Functional play is the next natural layer after exploratory play • Cause-and-effect toys and routines often create the safest bridge • Regulation and connection need to come before expansion • One small variation is more effective than pushing a full new skill • Readiness cues help us know when the stretch is safe • One-step actions become the building blocks for multi-step and pretend play • Joy and emotional safety keep the brain open for learning • Development unfolds in layers and cannot be rushed When we focus on small bridges instead of big leaps, play expands in a way that feels safe and sustainable. Try This • Identify one exploratory play pattern the child already loves • Join the action before offering a new idea • Add one simple cause-and-effect variation • Model one clear one-step action like push, drop, or press • Pause and wait without adding pressure • Track which one-step actions the child enjoys repeating Sometimes the most meaningful progress comes from one tiny bridge built on something the child already trusts. Related Resources & Links Autism Little Learners Membership www.autismlittlelearners.com/pod Play and Learn Functional Play and Autism Play-Based Learning for Autistic Children Honoring Diverse Styles of Play Fine Motor and Sensory Bins Gently Expanding Autistic Play: Tips For Parents and Educators Visual Support Starter Set  Visual Supports Facebook Group Functional play is not about replacing exploratory play. It is about building on the sensory and emotional safety that exploratory play already provides. When we honor the stage and expand gently, new layers of learning unfold naturally.  

In this episode, we continue the play series with an important reframe for educators, therapists, and caregivers: Exploratory play is not a problem to fix. It is a stage to understand. When a child dumps toys, spins wheels, mouths objects, drops items, or repeats the same action over and over, it can be easy for adults to feel pressure to stop it. But what if the behavior isn't the problem? This episode explores why exploratory play is a foundational stage of development, especially for young autistic children, and how repetitive sensory-driven play often supports regulation, motor planning, focused attention, and early cause-and-effect learning. Instead of rushing children into more "functional" play, we'll walk through how to understand the sensory and developmental purpose behind exploratory play and how to gently shape it into the next stage without removing what already feels safe. This conversation is especially helpful for classrooms and therapy spaces where dumping, dropping, spinning, and repetitive object play can feel chaotic but are actually providing important information to the child's nervous system. In This Episode, You'll Learn • Why exploratory play is a real developmental stage, not a behavior problem • What children are learning when they dump, spin, drop, or mouth objects • Why autistic children may remain in this stage longer • The difference between safe boundaries and eliminating play entirely • Why adult anxiety around "stuck" can lead to premature redirection • How exploratory play naturally becomes functional play through cause and effect • Why repetitive play often supports nervous system regulation • Supportive classroom shifts that make exploratory play feel safer and more intentional • How to expand exploratory play without taking away the joy Key Takeaways • Exploratory play is sensory-driven learning • Repetition helps the nervous system gather information and build predictability • Dumping, spinning, dropping, and mouthing are forms of information gathering • Regulation often needs to come before more complex play can emerge • Boundaries can shape play safely without removing the sensory experience • Cause-and-effect routines create a natural bridge into functional play • Classroom environments feel calmer when exploratory play is planned for • The goal is to respect the stage, not rush past it When we stop trying to "fix" exploratory play, we make space for regulation, connection, and authentic development. Try This • Observe what sensory pattern the child is repeating • Ask what need the repetitive action might be meeting • Create safe dumping, dropping, or spinning spaces in the classroom • Add one small cause-and-effect variation like a ramp, tube, or drop zone • Use boundaries that shape safety without removing the experience • Plan sensory-rich play intentionally into the classroom day Often the most supportive shift is moving from correction to curiosity. Exploratory play is not something children need to be rushed out of. It is a sensory-rich stage that supports regulation, learning, and development. When we respect it as the foundation it is, the next stage of play unfolds much more naturally. Related Resources & Links Autism Little Learners Membership www.autismlittlelearners.com/pod Play and Learn Functional Play and Autism Sensory Play and Autism Play-Based Learning for Autistic Children Honoring Diverse Styles of Play

Send us Fan MailHow close is pathology AI to making decisions that matter in real workflows, real trials, and real patient care?In this episode of DigiPath Digest, I review five recent papers that approach that question from very different angles. We look at multimodal survival prediction in cervical cancer, pathology-driven response assessment in neoadjuvant immunotherapy for head and neck squamous cell carcinoma, AI-assisted Ki-67 scoring in pulmonary neuroendocrine neoplasms, automation and AI in hematologic diagnostics, and AI-based qFibrosis readouts from the Phase 3 MAESTRO-NASH trial.What I liked about this set of papers is that they do not all tell the same story. Some show clear progress. Some show where AI already works well as an adjunct. Others make it very clear that validation, governance, reproducibility, and workflow design still matter just as much as model performance.Key topics and timestamps00:00 Introduction, Easter edition, and community updates 00:51 USCAP recap, signed book giveaway, and free Digital Pathology 101 PDF 02:04 Partnerships, lab automation preview, and what's coming in this episode 03:25 Multimodal deep learning for cervical cancer survival prediction 13:00 Why pathology may be a better response endpoint than radiology in neoadjuvant HNSCC immunotherapy 23:09 Ki-67 scoring in pulmonary neuroendocrine neoplasms: pathologists vs two AI systems 33:46 AI, digital morphology, and automation in hematologic diagnostics 43:29 qFibrosis, digital biomarkers, and the MAESTRO-NASH Phase 3 trial 51:57 Closing thoughts, community updates, and Easter promotion Resources Deep Learning Can Predict the Overall Survival of Cervical Cancer Based on Histopathological Image, Gene Mutation and Clinical Information https://pubmed.ncbi.nlm.nih.gov/41902378/ Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers https://pubmed.ncbi.nlm.nih.gov/41899621/ Ki-67 Proliferation Index in Pulmonary Neuroendocrine Neoplasms: Interobserver Agreement Among Pathologists and Comparison of Two Artificial Intelligence-Based Image Analysis Systems https://pubmed.ncbi.nlm.nih.gov/41898274/ Molecular Pathology, Artificial Intelligence, and New Technologies in Hematologic Diagnostics: Translational Opportunities and Practical Considerations https://pubmed.ncbi.nlm.nih.gov/41897649/ Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial https://pubmed.ncbi.nlm.nih.gov/41895606/Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. Schattenberg JM, Bedossa P, Guy CD, et al. Journal of Hepatology 2026; https://doi.org/10.1016/j.jhep.2026.03.021.Episode Summary: In this deep dive, we explore how artificial intelligence is revolutionizing the way we measure liver disease recovery. We examine a groundbreaking 2026 Phase III clinical trial (MAESTRO-NASH) that compared traditional human pathologist staging against an AI-driven digital pathology tool called qFibrosis. The study forces us to reconsider our clinical gold standards by asking: what if AI can detect subtle biological healing that the experienced human eye completely misses?In This Episode, We Cover:• The Silent Epidemic: Understanding Metabolic dysfunction-associated steatohepatitis (MASH), a progressive, active form of fatty liver disease linked to cardiovascular risk and cirrhosis. We discuss why precisely tracking the reversal of liver fibrosis is crucial for patient outcomes.• The "Ordinal" Problem: Why the current "gold standard"—human pathologists assigning a simple ordinal score (like Stage F1, F2, or F3)—is subjective and fails to capture the dynamic, nuanced reality of fibrosis progression and regression.• The AI Microscope (SHG & qFibrosis): ◦ SHG (Second Harmonic Generation): An imaging technique that takes advantage of the physical properties of collagen to map out the three-dimensional architecture of the liver. ◦ qFibrosis: An AI-driven analysis tool that evaluates up to 184 distinct features of liver collagen (like string length, width, and intersections) across different regions of the liver lobule, providing a continuous, hyper-detailed assessment rather than a basic category.• The Showdown - Humans vs. AI: Using data from 966 patients in the MAESTRO-NASH trial, we compare how human pathologists and the AI evaluated liver biopsies at baseline and week 52 to test the efficacy of the drug resmetirom.• The AI's "Aha!" Moment (Seeing the Invisible): The most shocking finding of the study occurred in the "non-responder" group. Even when human consensus reads declared certain patients had no histological improvement, the AI detected significant, continuous reductions in liver fibrosis (qFC scores). The digital pathology tool was able to pick up on subthreshold, early matrix remodeling that was entirely invisible to standard manual scoring.• Mapping the Liver's Healing: The AI proved its biological accuracy by successfully linking its spatial data to real-world clinical outcomes. The AI found that specific regional changes—particularly in the portal tract—strongly correlated with non-invasive liver stiffness tests like Magnetic Resonance Elastography (MRE).Key Takeaway: AI isn't here to replace human pathologists; it is a hyper-sensitive tool designed to uncover hidden data patterns. By detecting continuous, region-specific changes in liver collagen, AI digital pathology can identify early therapeutic responses to MASH treatments that traditional staging misses, fundamentally changing how we track disease reversal and personalize medicineSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

How do you quickly get an understanding of what's inside a new set of data? How can you share an exploratory data analysis with your team? Christopher Trudeau is back on the show this week with another batch of PyCoder's Weekly articles and projects.

Adam Hamilton, Church of the Resurrection Pastor, On Exploratory Run For U.S. Senate in Kansas | 3-3-26See omnystudio.com/listener for privacy information.

Ben Stookesberry paddles kayaks in his home state of Montana, and around the world. In his teen years he learned to make home movies showing off his rollerblading moves, and in college he learned to kayak. Today he blends the paddling and film making as he runs rivers in global settings. He has created deep and lasting friendships in his travels, and returns to rivers again and again, to paddle more stretches, to learn more, and sometimes to engage in protection work. In this episode, Ben talks through all of this with us, and goes into depth about his current paddling and film efforts on the Jatunyacu and Mulatos Rivers in Ecuador.GUESTSBen Stookesberry@benstookesberryBio @ KokatatBio @ Jackson KayakLatest Film:  ¡Ay Chihuahua!Diego Robles:  @ecuskayaker RESOURCESEcuadorian Rivers Institute@ecuadorianriversSteven Donzinger storySavages, book, by Joe Kane PADDLERS TO FOLLOW@ecuskayaker (Diego)@williehenkel@wyatt_doyle@salmonsourcetosea@elizabeth.tobey@brookehess@oceansandmountains (Hailey)@pedroolivakaiak@riverratmountainkat@mayuwarmikayak@teepee_boys SPONSORSDenver Area Nissan Dealers@nissanusa     THE RIVER RADIUSWebsiteRunoff signup (episode newsletter)InstagramFacebookApple PodcastSpotifyLink Tree

[DATA CORRUPT]

A 14-year-old from Milwaukee is a new host of a Beatles show on satellite radio. He's a non-speaker who learned to communicate through adaptive technology. And, as we continue to look back at some of our favorite stories of the year, we'll take you to the site of what could become a gold mine.

Hammad Bashir, CTO of Chroma, joins the show to break down how modern vector search systems are actually built from local, embedded databases to massively distributed, object-storage-backed architectures. We dig into Chroma's shared local-to-cloud API, log-structured storage on object stores, hybrid search, and why retrieval-augmented generation (RAG) isn't going anywhere.Follow Hammad:Twitter/X:  https://twitter.com/HammadTimeLinkedIn: https://www.linkedin.com/in/hbashirChroma: https://trychroma.comFollow Aaron:Twitter/X:  https://twitter.com/aarondfrancis Database School: https://databaseschool.comDatabase School YouTube Channel: https://www.youtube.com/@UCT3XN4RtcFhmrWl8tf_o49g  (Subscribe today)LinkedIn: https://www.linkedin.com/in/aarondfrancisWebsite: https://aaronfrancis.com - find articles, podcasts, courses, and more.Chapters:00:00 – Introduction From high-school ASICs to CTO of Chroma01:04 – Hammad's background and why vector search stuck03:01 – Why Chroma has one API for local and distributed systems05:37 – Local experimentation vs production AI workflows08:03 – What “unprincipled data” means in machine learning10:31 – From computer vision to retrieval for LLMs13:00 – Exploratory data analysis and why looking at data still matters16:38 – Promoting data from local to Chroma Cloud19:26 – Why Chroma is built on object storage20:27 – Write-ahead logs, batching, and durability26:56 – Compaction, inverted indexes, and storage layout29:26 – Strong consistency and reading from the log34:12 – How queries are routed and executed37:00 – Hybrid search: vectors, full-text, and metadata41:03 – Chunking, embeddings, and retrieval boundaries43:22 – Agentic search and letting models drive retrieval45:01 – Is RAG dead? A grounded explanation48:24 – Why context windows don't replace search56:20 – Context rot and why retrieval reduces confusion01:00:19 – Faster models and the future of search stacks01:02:25 – Who Chroma is for and when it's a great fit01:04:25 – Hiring, team culture, and where to follow Chroma

In this episode, Dr Elle Wadsworth talks to Dr Tim Mackey and Dr Doug Roehler. Tim is a professor in the Global Health Program at UC San Diego and the CEO and co-founder of S-3 Research, and Doug is the Cannabis Research Unit lead in the Department of Policy and Research for California's Department of Cannabis Control. The interview covers Tim and Doug's research article exploring the health benefit claims of cannabis products on online marketplaces in the United States. Why exploring health benefit claims on cannabis products was an important topic to investigate [01:20]What are cannabis-derived products? [03:07]What are the online marketplaces ‘Leafly' and ‘Weedmaps'? [03:35]Examples of health benefit claims [05:00]The main findings of the study [07:33]The cannabis regulatory environment in the US [10:20]The differences in health claims between different types of cannabis products [12:20]The methodology used in the study that brought together data scientists and public health researchers [14:11]The health claims that surprised Tim and Doug [18:31]About Elle Wadsworth: Elle is an academic fellow with the Society for the Study of Addiction. She is based at the University of Bath with the Addiction and Mental Health Group and her research interests include drug policy, cannabis legalisation, and public health. She has a BSc in Chemistry, an MSc in Addiction Studies, and a PhD in Public Health. About Tim Ken Mackey: Tim is a Professor in the Global Health Program at UC San Diego and the CEO and co-founder of S-3 Research, a public health data science company originally created from a Challenge.gov award. He is also the Director of the Global Health Policy and Data Institute and the Editor-in-Chief of JMIR Infodemiology. He has co-authored over 270 manuscripts on topics including global health, technology, data science, substance use disorder, and health policy. Dr Mackey is an entrepreneur and scientist working on technology innovation to address public health challenges. About Douglas Roehler: Doug leads the Cannabis Research Unit in the Department of Policy and Research for California's Department of Cannabis Control. Previously, he was a health scientist and epidemiologist in the Division of Overdose Prevention at the CDC, where he primarily served in the CDC's Cannabis Strategy Unit. He has published extensively on cannabis topics in peer-reviewed journals and governmental reports, appeared on national podcasts, and represented the CDC in the national media. He has published widely on several other topics, including injury prevention, drug overdose and substance use, youth prevention, syndromic surveillance, traffic crashes, and youth violence. Declarations of Interest: Tim Mackey is the CEO and co-founder of the company S-3 Research and holds equity/ownership in the company. S-3 Research is a small business that has received funding through government contracts and grants for professional and technology services including on topics related to substance use disorder.Original article: Exploratory analysis of United States-based cannabis product health benefit claims on online marketplaces https://doi.org/10.1111/add.70177The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

In this JIMD Shortcast, Allyson Terrell and Katie Sapp explore the real-world challenges of newborn screening for lysosomal storage disorders, based on a survey of healthcare professionals working at the front line of implementation. The study highlights the limitations of single-tier screening, the value of multi-tier testing, and the growing importance of multidisciplinary collaboration to improve diagnostic clarity and patient outcomes. Exploratory Study on the Challenges of Newborn Screening for Lysosomal Storage Disorders Emphasizes the Need for Multitier Testing and Collaborative Approaches to Management A. Terrell, et al https://doi.org/10.1002/jmd2.70027

And when you need each———Tomorrow, I'm going to tell you about the 3 kinds of inflection points high achievers face in their careers, and why you need Exploratory Mode when you're in them.Subscribe to my email newsletter so you don't miss a thing: https://poojav.substack.com/And if you've been stuck for more than two weeks on a stress, productivity, performance, or purpose question…Come talk to me and let's crack it together: https://poojavcoaching.com/contact

Show NotesIn this special live episode from the 2025 North American Congress of Clinical Toxicology (NACCT), Ryan takes you inside the conference to hear directly from the researchers themselves. Covering 11 abstracts that span high-stakes management decisions, surprising case reports, and challenges to toxicology dogma, this year's highlights feature everything from amlodipine overdoses to naturopathic misadventures, metformin-associated blindness, and more. The show kicks off with a foreword from Ryan and Dr. Jon Cole (abstract co-chair for AACT) discussing some of their favorite research from the conference. If you couldn't make it to NACCT or just want to catch up on some of the most impactful new research in our field, this episode will give you a front-row seat. Check below for links to the published abstracts, the full list of studies discussed, and timestamps for where you can hear each one.Link to published abstract manuscriptForeword with Dr. Jon Cole 10:24 #7. Is beta blocker toxicity associated with hypoglycemia?Lead author: Dr. Megan Audette, MD17:58 #237. V-A ECMO as a treatment for vasoplegic shock in amlodipine poisoning: a comparisonLead author: Dr. Daniel Tirado, MD27:59 #247. Blocked but not beaten: ECMO's role in severe amlodipine toxicity – a poison center case seriesLead author: Dr. Carlos Saldarriaga, MD28:39 #26. Amlodipine double-dose therapeutic errors reported to Poison CentersLead author: Johanne Freeman30:19 #27. Dosing on the edge: unpacking inadvertent amlodipine ingestions reported to a single poison centerLead author: Dr. Tiana Patriarca, PharmD33:44 #292. Intravenous administration of sodium zirconium cyclosilicate resulting in deathLead author: Dr. Stephen Thornton, MD Researcher interviews43:57 – #21. Quantitative analysis of amlodipine removal by plasmapheresisGuest: Dr. Keahi Horowitz, MD – Acute and Intensive Care Research Award winner48:14 – #23. Relationship between reported ingestion dose and outcome in amlodipine poisoningGuest: Dr. Colleen Cowdery, MD51:18 – #24. Management of severe amlodipine toxicity with high-dose calcium aloneGuest: Dr. Vincent Ma, MDHigh dose norepinephrine in amlodipine overdose Case report of calcium death 56:37 – #70. Iatrogenic exposure to long-acting buprenorphine injectable in an opioid-naïve patientGuest: Dr. Conor Young, MD59:52– #182. Left in the dark: a case of blindness in the setting of metformin toxicityGuest: Dr. Madison Bombard, MD61:52 – #169. Just because it's natural doesn't mean it's safe: a case of pediatric toxicity from topical and herbal remediesGuest: Dr. Aria Darling, MD64:12 – #203. Serotonin syndrome after vaping MoocahGuest: Dr. Connor Murphy, MD66:47 – #307. Intravenous ozone autohemotherapy: a retrospective observational case seriesGuest: Nicole McLarty 71:06 – #134. Do they really need n-acetylcysteine? Exploratory analysis of outcomes in patients with elevated liver function

Tony Cardella is a seasoned software engineer based in Houston, Texas. With a robust background in enterprise development, Tony brings deep expertise in the .NET Framework (C#), Python, and cloud platforms including Microsoft Azure and Amazon Web Services. His technical repertoire spans both relational databases — such as SQL Server, MySQL, and PostgreSQL — and NoSQL solutions like Azure Cosmos DB.   Tony is a strong advocate for developer productivity tools, frequently leveraging JetBrains products including ReSharper, DataGrip, PyCharm, and Rider, as well as Visual Studio. Outside the world of code, Tony is equally passionate about strength training, whether he's lifting weights himself or coaching others in the discipline.   Topics of Discussion: [1:34] Tony shares his career journey, starting with a consulting company that reached out to him while he was job hunting. [3:17] NCrunch is an automated testing tool that runs unit tests continuously, focusing on impacted tests. [5:08] Challenges and benefits of NCrunch, and why would we need to use it? [7:44] Tony shares his approach to unit testing, focusing on covering 80% of the code with minimal effort and addressing the remaining 20% as needed. [8:51] The importance of not over-investing in unit tests that may not provide significant value. [11:47] Tony explains how Ncrunch provides code coverage metrics and visual indicators of covered and uncovered code. [12:59] The tool's ability to show exactly where unit tests are failing, without needing to dive into stack traces. [13:51] Distributed processing and integration tests. [27:44] The challenges of running integration tests with external dependencies, such as databases. [29:18] Exploratory testing and code quality. [32:34] Tony emphasizes the value of unit tests in codifying tribal knowledge and ensuring code quality.   Mentioned in this Episode: Clear Measure Way Architect Forum Software Engineer Forum Tony Cardella Lightning Talks! The Code Gorilla Survey: Fixing Bugs Stealing Time from Development NCrunch   Want to Learn More? Visit AzureDevOps.Show for show notes and additional episodes.

Kann man den Hunger einfach wegspritzen? Und was passiert eigentlich, wenn du plötzlich keinen Appetit mehr hast?Die Medien sind voll von Mythen, Halbwissen und Marketing rund um Ozempic, Wegovy und anderen der sogenannten „Abnehmspritzen“. In dieser Episode bekommst du den Überblick, den du brauchst – um Dir eine eigene Meinung zu bilden.Du erfährst:warum viele Menschen nicht zunehmen, obwohl sie mehr essen – und andere schon bei normalen Portionen zunehmen,was GLP-1-Wirkstoffe mit Spielsucht, Alkohol und impulsivem Verhalten zu tun haben,warum viele Patienten nach dem Absetzen der Spritze schneller wieder zunehmen, als sie abgenommen haben,und warum es gefährlich sein kann, unter diesen Medikamenten zwar Gewicht zu verlieren – aber dabei Muskeln zu verbrennen statt Fett.Und wenn Du ohnehin sagst: „Spritze? Kommt für mich nicht infrage“, lohnt diese Episode – weil sie Dir hilft, den Mechanismus hinter Hunger, Sättigung und Gewohnheiten besser zu verstehen. Und damit auch Deinen eigenen Körper effektiver zu steuern.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Mehr zum Thema:Podcast: Folge 502: Ratgeber Nahrungsergänzung – mit Ernährungsmediziner Niels Schulz-RuhtenbergQuellen:Wilding, J. P. H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.Garvey, W. T. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091.Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.Ryan, D. H. & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194.Marx, N. et al. (2022). GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation, 146(24), 1882–1894.Lincoff, A. M. et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.Karakasis, P. et al. (2023). Effect of tirzepatide on renal function in type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism.Ida, S. et al. (2021). Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Current Diabetes Reviews, 17(3), 293–303.Wilding, J. P. H. et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Suppl. 1), A16–A17.Gorgojo-Martínez, J. J. et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine Research, 12(1).Tantawy, S. A. et al. (2017). Effects of physical activity and diet control to manage constipation in middle-aged obese women. Diabetes, Metabolic Syndrome and Obesity, 10, 513–519.Jastreboff, A. M. et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526.***Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this episode we discuss exploratory experimentation, an iterative process used by scientists to better understand phenomena. We ask why exploratory research seems to be valued less in science, the importance of lab notebooks, and what makes for a good exploratory study.   References: Steinle, F. (2016). Exploratory experiments: Ampère, Faraday, and the origins of electrodynamics. University of Pittsburgh press. Skinner, B. F. (1956). A case history in scientific method. American Psychologist, 11(5), 221–233. Popper, K. R. (1962). Conjectures and refutations: The growth of scientific knowledge. Routledge. Ditroilo, M., Mesquida ,Cristian, Abt ,Grant, & and Lakens, D. (2025). Exploratory research in sport and exercise science: Perceptions, challenges, and recommendations. Journal of Sports Sciences, 43(12), 1108–1120. https://doi.org/10.1080/02640414.2025.2486871 Paul Meehl's Philosophical Psychology Lectures: https://meehl.umn.edu/video Höfler, M., Scherbaum, S., Kanske, P., McDonald, B., & Miller, R. (2022). Means to valuable exploration: I. The blending of confirmation and exploration and how to resolve it. Meta-Psychology, 6. https://doi.org/10.15626/MP.2021.2837  

Joel and Aaron unpack a recent client project where the only spec was “make these two systems talk.” They share how console-level prototypes helped them clarify data mapping, test tricky scenarios, and keep the client looped in without over-building a UI. If you've ever had to code first and document later, this one's for you.(00:00) - Bridging two APIs with minimal specs (03:30) - Choosing an exploratory workflow over full UI (06:00) - Console closures for quick, testable steps (09:15) - Hand-off strategy: letting others poke the prototype (11:45) - Silly bit

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prevalence, Risk Factors, and Prognosis for Fontan-Associated Liver Disease: A Systematic Review and Exploratory Meta-Analysis.

Special episode from the east with the president of SD Trucking and Auto Association's Christine Erickson. We chat about Lyft's SD origin, and other SF issuez. A little background on Christine, Exploratory committees, property tax relief, kicking footballs, Minihaha county GOP, Tik Tok meetings and golfing in Ireland.@DakotaTownHall@Jakeschoenbeck@Cvinny4 Hosted on Acast. See acast.com/privacy for more information.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Sleep and Seizures: Emerging Insights From AAN 2025," Nancy Foldvary-Schaefer, DO, director of the Sleep Disorders Center at Cleveland Clinic, reflected on key sleep-related topics presented at this year's AAN Annual Meeting. She highlighted the growing clinical interest in underrecognized conditions like idiopathic hypersomnia and narcolepsy, stressing the need for better awareness and earlier diagnosis. Foldvary-Schaefer also detailed the development of the Sleep by Cleveland Clinic mobile app, designed to improve screening for common sleep disorders with validated tools and real-time resources. Additionally, she discussed new findings on the prevalence of obstructive sleep apnea in adults with epilepsy, pointing to the importance of routine sleep screening in this population, regardless of seizure severity. Finally, she shared exploratory data on SSRI use and peri-ictal respiratory patterns in epilepsy, offering new perspectives on potential protective mechanisms tied to SUDEP risk. Looking for more neuromuscular discussion? Check out the NeurologyLive® Sleep disorders clinical focus page. Episode Breakdown: 1:00 – Key sleep topics discussed at AAN 2025 and the growing interest in hypersomnia 5:45 – Development and purpose of the SLEEP mobile app by Cleveland Clinic 10:35 – Findings on obstructive sleep apnea prevalence in adults with epilepsy 15:05 – Neurology News Minute 17:10 – The need for sleep disorder screening in epilepsy clinical trials 19:45 – Exploratory findings on SSRI use and respiratory patterns in patients with epilepsy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Pre-Filled Syringe Administration for FcRn Modulator Efgartigimod FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine FDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5 Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics: Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30) Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49) The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25) Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18) TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50) Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09) The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02) Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36) Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23) Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56) CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04) CME information and select publications

 In this JCO Article Insights episode, Lauren Shih summaries "Longitudinal Results From the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment in American College of Surgeons–Accredited Cancer Programs" by  Jessica L. Burris, et al published November 19, 2024. Come back for the next episode where JCO After Hours host, Dr. Davide Soldato interviews the author of the JCO article discussed, Dr. Jessica Burris. TRANSCRIPT Lauren Shih: Hello and welcome to JCO Article Insights. I'm your host Lauren Shih, and today we will be discussing the article, “Longitudinal Results From the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment in American College of Surgeons–Accredited Cancer Programs” by Dr. Jessica Burris and colleagues published in the March issue of JCO. This study reports the finding of the Just ASK Initiative, an effort aimed at improving universal smoking assessment in cancer programs nationwide. We know that smoking after a cancer diagnosis is associated with numerous negative outcomes including worse survival, increased treatment related complications, poorer quality of life and higher healthcare costs. Patients who smoke are also at increased risk for cancer recurrence and second primary malignancies. Despite these risks, data show that a significant number of patients with newly diagnosed cancer still smoke and around 15% of cancer survivors continue smoking. Recognizing this discrepancy, national oncology organizations strongly recommend routine smoking assessment and cessation support as part of standard cancer care. However, despite these guidelines, smoking assessment and cessation assistance remain inconsistent across oncology practices. Surveys show that most National Cancer Institute designated cancer centers have insufficient resources to effectively support smoking cessation efforts. To address this gap, several large scale initiatives have been launched, including efforts by the National Cancer Institute, the Canadian Partnership Against Cancer, and the American College of Surgeons. The largest of these initiatives, through the American College of Surgeons, is the subject of our report today. In 2022, the American College of Surgeons introduced the Just ASK Quality Improvement Program with the goal of increasing routine smoking assessment. As member institutions, accredited programs are required to complete at least one quality improvement program annually. And in 2022, 40% of programs chose to participate in Just ASK. The primary goal of this quality improvement program was to ask at least 90% of newly diagnosed cancer patients about their smoking status. Offering smoking cessation support was encouraged, but not a mandatory component or primary endpoint for the initiative. To implement Just ASK, participating programs used a well-established Plan-Do-Study-Act methodology which is a structured, iterative approach for improving healthcare processes. Programs used local quality improvement teams and resources for implementation and had access to online training, educational webinars, and technical resources to help integrate smoking assessment into routine care. Programs completed three surveys: a baseline survey reflecting smoking assessment practices in the year before Just ASK; a midpoint survey after six months of participation; and a final survey after one year in the program. The surveys assess program characteristics, barriers to smoking assessment, readiness to change, and the frequency of smoking related clinical practices such as asking about smoking, documenting smoking status, and advising smoking cessation. Programs reported on implementation strategies they adopted to improve smoking assessment. Finally, programs reported the number of newly diagnosed cancer patients they saw, how many were asked about their smoking status and how many were identified as current smokers during each reporting period. Results from 762 participating cancer center programs were analyzed. The programs represented a diverse mix of practice sites with over 50% identified as community based. Retention in the program was high, with nearly 90% of programs completing the final survey. Most programs reported moderate organizational readiness at baseline along with an average of 4.6 implementation barriers to conducting routine smoking assessment. Barriers included factors such as lack of time, competing clinical priorities, and lack of designated tobacco treatment specialists. At baseline, the ask rate was 87.8% and this increased to 91.9% at the final survey, meeting the previously identified goal for the initiative. Throughout the initiative, programs reported increases over time in assessing smoking status, in advising patients who smoked and quit, and in documenting these assessments and recommendations in the medical record. Importantly, the smoking rate among patients asked ranged from 18.5% to 19.8% across the three surveys, demonstrating a high rate of current smoking among newly diagnosed cancer patients. The most common implementation strategies adopted by programs to promote change included gaining leadership support, improving documentation on the electronic health record, and training staff and providers. There were no major differences in implementation strategies based on program type. Organizational readiness was positively associated with better smoking assessment practices, and implementation barriers had a negative impact, although not always statistically significant. The number of implementation strategies used by programs showed a positive, significant association with smoking assessment practices at the final survey. Exploratory analyses did not suggest that program type or patient volume had a consistent relationship with the outcomes. Although the primary goal of Just ASK was smoking assessment and not cessation assistance or intervention, programs did report on cessation related practices. For example, programs reported providing education or self-help materials increased from 26% to 48%, referrals to tobacco treatment specialists increased from 25% to 35%, and referrals to quit lines increased from 27% to 45%. Prescribing or recommending FDA approved cessation medications increased from 17% to 21%. In conclusion, Just ASK is the largest nationwide initiative to standardize and improve smoking assessment in cancer care. It successfully improves smoking assessment across a diverse range of cancer practices, ensuring that hundreds of thousands of newly diagnosed cancer patients were asked about their smoking status. As nearly 20% of the cohort reported smoking, this represents a critical first step in helping patients access smoking cessation resources. Participating programs demonstrated small but sustained practice changes in smoking assessment, meeting the a priori determined goal of a 90% ask rate. However, as a quality improvement initiative, Just ASK was not designed as a clinical trial, so conclusions regarding the efficacy of the program as an intervention are limited. Selection bias may have also played a role in the findings as program participation was voluntary. Additionally, the initiative lasted just one year and while the initial improvements were steady during that time, the long term impacts of Just ASK on smoking assessment remain uncertain. Looking ahead, the American College of Surgeons recently completed the Beyond ASK initiative. This initiative is designed to go a step further and focuses on improving smoking cessation assistance and we await the results. The Just ASK initiative demonstrates the routine smoking assessment is feasible to complete as routine cancer care. This assessment is essential as identifying patients that smoke is the first and critical step towards offering smoking cessation support, which in turn can improve health outcomes and reduce cancer treatment costs. While Just ASK was a success in increasing assessment, the challenge now is ensuring that smoking cessation support is readily available for all patients who need it. Thank you for listening to JCO Article Insights. Please give us a rating or review and subscribe so you never miss a JCO episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Shari talks with Zach Weber about his career as a multidisciplinary and mixed-media artist. Zach is 27 years old and has exhibited in institutions such as Art Miami, 2022, the Zolla/Lieberman ...

Do you want more active engagement in your classroom?  Today's episode is an audio version of my training titled “3 Simple Strategies To Foster Engagement, Play & Communication In Autistic Preschoolers”. The training covers transforming dumping & throwing toys into structured play-based activities, the importance of following a child's interests, the need for flexibility in teaching approaches, and integrating augmentative and alternative communication (AAC) into play-based learning. The session aims to empower educators and parents with actionable insights to support young autistic children effectively.  Keep listening to learn more! Takeaways ●     Ideas for transforming dumping and throwing behaviors into structured play activities ●     Exploratory play is a natural part of development for all children, including autistic children ●     Following a child's lead means observing their interests and engaging with them at their level ●     Identifying deep interests can significantly enhance engagement and learning ●     Flexibility in teaching allows for real-time adjustments to meet children's needs ●     Integrating AAC into play creates a low-pressure environment for communication ●     Modeling language without expectation fosters confidence in using AAC ●     Play should be fun, reciprocal, and pressure-free to encourage natural exchanges ●     Using children's interests in lesson plans can make learning more meaningful ●     Building trust through play is crucial for developing relationships with autistic children  Links 3 Simple Strategies Handout: https://drive.google.com/file/d/1q2MIOQ9Hn5TZBVEAnYQQOdzDBqw7uNj2/view?usp=sharing Watch the YouTube version with slides showing the concepts: https://youtu.be/Y9Z1Ok-f84U Themed play visual supports: https://www.teacherspayteachers.com/Product/Autism-Play-Themed-Visual-Supports-For-Special-Education-8414926  Put-In Activity Challenge: https://autismlittlelearners.thrivecart.com/put-in-challenge-2024/  You may also be interested in these supports: 1.    Visual Support Starter Set 2.    Visual Supports Facebook Group 3.    Autism Little Learners on Instagram 4.    Autism Little Learners on Facebook

IN HOC PROGRAMMA’ ‘DE WHEELOCK 6th , Ed. capite tertio, paginis 17-23: de nominibus et adiectivis omnibus casibus ex secunda declinatione, de appositione, et de verborum ordine in oratione vel sententia’ ‘SEQUIMUR’ [QUIA “NUNTII IN LINGUA LATINA” ‘INSTRUMENTUM’ ‘AD LATINUM DISCENDUM ET DOCENDUMQUE’ ‘EST’]. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET GALLICA’ ‘*AUDIS’! CIVITATES FOEDERATAE AMERICAE ET RUSSIA CONTRA EUROPAM ET UCRAINAM. 14 TRANSLATIO A FERNANDA SOLÍS VERSAM EST. ‘*CIVITATES FOEDERATAE AMERICAE ET *RUSSIA ‘COLLOQUIA’ ‘DE UCRANIA’ , ‘SINE KIOVIA NEQUE UNIONE EUROPAEA ‘*INEUNT’ . // ‘*EUROPA PERTURBATA ‘*EST’ ‘QUIA DEFENSIONEM SUAM SINE AMERICA ‘COGITARE’ ‘INDIGET’ . AEGYPTO. TRANSLATIO AB ALISSA SOUZA VERSAM EST. ‘*CAIRUS’ ‘SUUM CONSILIUM’ ‘PRO GAZA’ ‘*PARAT’. // ‘*NATIONES ARABICAE’ ‘SUAS OPTIONES’ ‘IMPROVISO IMPETU’ ‘A DONALDO TRUMP, CIVITATUM FOEDERATAE AMERICAE PRAESIDE,’ ‘CAPTAE’ ‘*PRAEPARANT’. //. ‘*AEGYPTUS’ ‘CONSILIUM’ ‘DE REFICIENDO HOC TERRITORIO PALAESTINENSI’ ‘CUM ARGENTARIA MUNDANA’ ‘*EXCOLIT’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET ITALICA’ ‘*AUDIS’! CIVITAITS VATICANAE STATU. ‘PAPA *FRANCISCUS’ ‘IN VALETUDINARIO’ ‘AD ANALYSES FACENDUM’ ‘*EST’ . // ‘*FRANCISCUS, PAPA ECCLESIAE CATHOLICAE ROMANAE 15 A TERTIO DECIMO DIE MARTIIS MENSE ANNO DOMINI BIS MILLÉSIMO DECIMO TERTIO,’ ‘IN VALETUDINARIO’ ‘*MANET’ [QUIA ‘ANALYSES’ ‘MORBOS MULTIPLICES’ ‘*OSTENDUNT’]. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET GERMANICA ‘*AUDIS’! TRANSLATIO AB ALISSA SOUZA VERSAM EST. UCRAINA. BELLATOR SOLITARIUS. // [CUM ‘*RUSSIA’ ‘URAINAM’ ‘*INVADEBAT’], ‘*VLADIMIRUS ZELENS’KYJ, UCRAINAE PRAESES’ ‘BELLUM DOMINATOR’ ET , ‘QUOMODO WINSTON CHURCHILL’ ‘PUTATUS EST’. // ‘ID EST: FORTIS ET FIRMUS’ . // ‘NUNC VERO’ ‘DONALDUS , TRUMP, DENUO CIVITATUM FOEDERATAE AMERICAE PRAESES’ , ‘EUM’ ‘RELIQUIT’. // ‘*ZELENS’KYJ’ ‘IPSE SIT’ ‘IAM *NESCIT’ . {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel 2 appositiones invenis, quae sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. 16 IN ORBE TERRARUM. ‘*AGE’, ‘ORBEM TERRARUM’ ‘*DIVIDAMUS’. // ‘FOEDUS’ INTER ‘TRUMP, ITERUM C-F-A PRAESES A DIE VICESIMO MENSE IANUARII HOC ANNO’ , ET ‘PUTIN, ITERUM FOEDERATIONIS RUSSICAE PRAESES A ANNO BIS MILLESIMO DUOCESIMO’ , UCRAINAM AESTUAT ET SOCIA CONCUTIT. // ¿‘INTER EOSNE’ ‘EUROPAE PACEM ET FUTURUM’ ‘*DECIDENT’? {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Nomina et adiectiva in secunda declinatione invenis? ¿2 appositiones invenis, quae sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET HISPANICA’ ‘*AUDIS’! MEXICO. MEXICOPOLIS. ‘AEROPLANA NON GUBERNATA SPECULATORIAS. // ‘TRUMP *REGIMEN’ ‘SEDIS CENTRALIS EXPLORATORIAE’ ‘AEROPLANA NON GUBERNATA SPECULATORIAS, ID EST , VEL VEHICULUM AERIUM EXPLORANS SINE GUBERNATOR, ’ ‘AD NARCOTICORUM CULINAS IN MEXICO INVENIENDUM’ ‘*UTUNTUR’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis? ¿1 appositiones invenis, quae 17 sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET RUSSICA’ ‘AUDIS’! TRANSLATIONES A SAID RAYMUNDO DELGADO VERSA SUNT. TRUMP ADVERSUS ZELENSKY. '*TRUMP' 'APROBATIONEM ZELENSKII' 'AD QUATTUOR PARTES EX CENTUM CECIDIT' '*DIXIT'. // 'ESTNE HOC VERUM?' // '*ORATIO DONALD TRUMP' 'ERGA UCRANIAM ET ERGA VOLODYMYR ZELESNKY, UCRAINAE PRAESES,' MAGIS HOSTILIS' '*FIT'. // '*TRUMP, DUX CIVITATIUM FOEDERATAE AMERICAE,' 'DIE DUODEVIGINTI FEBRUARII MENSE' '*ITERAVIT': 'SECUNDUM SUA SENTENTIAM', '*ELECTIONES PRAESIDENCIALES' 'IN UCRANIA IN MOMENTO FUTURO PROXIMO' '*HABENDAE ESSE'. // 'SECUNDUM TRUMP': ('HOC DICERE' '*NON PLACET') '*VALOR APROBATIONIS ZELENSKY' QUTUOR PARTES EX CENTUM TANTUM' '*EST'. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est?}. DENUO TRUMP ADVERSUS ZELENSKY. -"*EGO' 'STATUM' 'VENDERE NON *POSSUM."- // '*ZELENSKY' ['CUR PROPOSITIONEM CIVITATIUM 18 FOEDERATAE AMERICAE' 'DE OPIBUS MINERALIBUS' '*REIECIT']' *EXPLICAVIT'. // ET '*ZELENSKY' 'AD TRUMP', ['*QUI' 'ELECTIONES' 'IN UCRANIA' ' *PETIVIT']' *RESPONDIT'. // -"SI '*ALIQUIS' 'ME MUTARE' 'HOC TEMPORE' '*VULT', TUNC: ['*HOC' '*NON EFFICIET']. // PRAETEREA '*CORRUPTIO INFORMATIONIS' 'DE CASU VALORIS APROBATIONIS' 'A RUSIA' '*PROVENIT'.- // '*ADMINISTRATIO TRUMP' 'SUAM ATTITUDINEM ERGA RUSSIAM' '*LENIVIT'. // 'BELLUM '*NON APELLAT', SED 'CONTENTIONEM'. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET SINENSIS PINYIN’ ‘*AUDIS’! TRANSLATIONES A CASANDRA FREIRE VERSA SUNT. SINIS. ‘DIE QUATTUORDECIM FEBRUARII’ ‘*COLLOQUIUM’ ‘SUCHEI ANNI BIS MILLESIMO VICESIMO QUINTO’ ‘PROMOTIONIS PROGRESSIONIS ET INNOVATIONIS INTELLIGENTIAE ARTIFICIALIS’ ET ‘*COLLOQUIUM’ ‘POTESTATIS NOVAE INDUSTRIALIZATIONIS ARTIFICIALIS INTELLIGENTIAE’ ‘*EVENERANT’ . // ‘IN THEMATE’ ‘*TRACTANDO’ "*INTELLEGENTIA ARTIFICIALIS’ ET ‘BONA *QUALITAS’ ‘NOVUM FUTURUM’ ‘*DUCIT", ‘PLUS QUAM CENTUM’ ‘*EXEMPLA’ ‘[UT ROBOTA HUMANOIDES, [ID EST ROBOTUM CORPUS SIMILIS HOMINI], RATIONES MODERATORUM 19 INTELLIGENTIUM] ET ‘* EXEMPLARIA VIRTUALIUM INTERACTIVORUM’ [CUM MAGNA-SCALAE INTERACTIVA AI, [ ID EST INTELLEGENTIA ARTIFICIALIS]] ‘*REVELATI SUNT’ . {De Wheelock 6th Ed. Capite 2, ¿Nomen ex prima declinatione invenis quod quadruplex apparet?}. SINIS. ‘NOVAE INCLINATIONES, NOVA LOCA, NOVAE POTENTIAE’: ‘NOVI *MERCATUS’ ‘NOVUM VIGOREM OECONOMIAE SINENSIS ‘*DEMONSTRANT’ . // ‘PRIMO VER ‘*FESTO’ , [HOC DECLARANTE MUNDI HEREDITATIS] ‘*IUCUNDIUS EST’ ET ‘*MERCATUS NOVI ANNI’ ‘IN FLUMINE MERIDIANO’ ‘*VIVIDISSIMUM EST’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿Aliqua appositio invenis, quae est? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. LEXICON LEXICON EX “CIVITATES FOEDERATAE AMERICAE ET RUSSIA CONTRA EUROPAM ET UCRAINAM”… Nomina • America – America • Colloquia – Talks, negotiations • Civitates – States • Defensionem – Defense • Europa – Europe 20 • Foederatae – Allied (as a substantive: Allied States) • Kiovia – Kyiv • Russia – Russia • Unione – Union • Ucrania – Ukraine Adiectiva • Perturbata – Disturbed, troubled Verba • Cogito – I think, consider • Indigeo – I need, lack • Ineo – I enter, begin • Sum – I am LEXICON EX “AEGYPTO”… Nomina • Aegyptus – Egypt • Argentaria – Bank • Cairus – Cairo • Civitatum (genitivo plural de Civitas) – States • Consilium – Plan, decision • Foederatae – Allied (as a substantive: Allied States) • Gaza – Gaza • Impetu (ablativo de Impetus) – Attack, momentum • Mundana – World (as an adjective meaning "global") • Nationes – Nations • Optiones – Options, choices • Palaestinensi – Palestinian (adjective) • Praeses – President • Territorium – Territory Adiectiva 21 • Arabicae – Arabic • Captae – Captured, seized • Suas – Their own • Suum – Their own Verba • Excolo – I develop, cultivate • Paro – I prepare • Praeparo – I make ready, prepare LEXICON EX “CIVITAITS VATICANAE STATU”… Nomina • Analyses – Examinations, tests • Ecclesia – Church • Franciscus – Francis • Menses – Month • Morbos (acusativo plural de Morbus) – Diseases • Papa – Pope • Valetudinarium – Hospital Adiectiva • Catholica – Catholic • Multiplices – Multiple • Romana – Roman • Tertius – Third Verba • Maneo – I remain, stay • Ostendo – I show, reveal • Sum – I am LEXICON EX “UCRAINA”… Nomina • Bellator – Warrior • Bellum – War • Civitates – States 22 • Dominator – Ruler, master • Praeses – President • Russia – Russia • Ucraina – Ukraine • Zelens’kyj – Zelensky Adiectiva • Firmus – Strong, firm • Fortis – Brave, courageous • Solitarus – Lonely, solitary Verba • Nescio – I do not know • Sum – I am LEXICON EX “IN ORBE TERRARUM”… Nomina • Foederatio – Federation • Foedus – Treaty, alliance • Futurum – Future • Orbis – World, globe • Pax – Peace • Praeses – President • Russia – Russia • Socia – Ally • Ucraina – Ukraine Adiectiva • Russica – Russian Verba • Aestuo – I am in turmoil, I am agitated • Decido – I decide • Divido – I divide • Concutio – I shake, I disturb LEXICON EX “MEXICO”… Nomina • Aeroplanum – Airplane 23 • Culina – Kitchen (in this context: drug lab) • Mexico – Mexico • Regimen – Government • Sedes – Headquarters, seat • Vehiculum – Vehicle Adiectiva • Centralis – Central • Exploratorius – Exploratory, reconnaissance • Speculatorius – Surveillance, spy Verba • Invenio – I find, discover • Utor – I use (takes the ablative) LEXICON EX “TRUMP ADVERSUS ZELENSKY.”… Nomina • Aprobatio – Approval • Civitates – States • Dux – Leader • Electiones – Elections • Mensis – Month • Oratio – Speech, discourse • Praeses – President • Sententia – Opinion, judgment • Ucraina – Ukraine • Valor – Value Adiectiva • Foederatus – Allied • Futurus – Future • Hostilis – Hostile • Presidentialis – Presidential • Proximus – Near, close Verba • Dico – I say, speak • Fio – I become, happen 24 • Habeo – I have • Itero – I repeat • Placeo – I please, am agreeable • Sum – I am LEXICON EX “DENUO TRUMP ADVERSUS ZELENSKY.” Nomina • Administratio – Administration • Aprobatio – Approval • Bellum – War • Civitas – State • Contencio – Conflict, dispute • Corruptio – Corruption • Electio – Election • Informacio – Information • Minerale – Mineral • Opes – Resources, wealth • Russia – Russia • Status – State, condition • Valor – Value Adiectiva • Foederatus – Allied • Hoc – This • Suus – His, their own Verba • ApeIlo – I call, name • Efficio – I accomplish, achieve • Explico – I explain • Lenio – I soften, alleviate • Possum – I am able, I can • Provenio – I come forth, arise • Reicio – I reject • Respondeo – I reply, answer • Vendo – I sell 25 • Volo – I want, wish LEXICON EX “SINIS” … Nomina • Colloquium – Conference, discussion • Dies – Day • Exemplum – Example • Futurum – Future • Innovatio – Innovation • Intelligentia – Intelligence • Potestas – Power • Progressio – Progress • Promotio – Promotion • Qualitas – Quality • Ratio – System, method • Robotum – Robot • Themata – Theme, subject Adiectiva • Artificialis – Artificial • Humaniformis – Humanoid • Industrialis – Industrial • Interactivus – Interactive • Novus – New Verba • Duceo – I lead • Revelo – I reveal • Tracto – I handle, discuss LEXICON EX “SINIS” … Nomina • Economia – Economy • Flumen – River, stream • Hereditas – Heritage, inheritance • Mercatus – Market 26 • Mundi – World (genitive singular of Mundus) • Potentia – Power, potential • Vigor – Strength, vigor • Ver – Spring (season) Adiectiva • Novus – New • Sinensis – Chinese • Iucundus – Pleasant, enjoyable • Vividissimus – Very vivid, most vivid Verba • Demonstrato – I demonstrate • Vivo – I live SI NUNTII IN LINGUA LATINA TRADUCTOR ESSE VOLUERIS, QUAESO LITTERAM ELECTRONICAM AD lpesquera@up.edu.mx MITTAS’. If you would like to collaborate as a translator in Nuntii in Lingua Latina, please send an email to lpesquera@up.edu.mx

Send us a textIn the second installment of our deep dive into Therapy First and Gender Exploratory Therapy, hosts Juniper and Laurel, both licensed clinicians, expose the growing network of anti-trans organizations operating under the guise of “evidence-based” care.We break down the interconnected web of groups like GenSpec, the Society for Evidence-Based Gender Medicine (SEGM), and Our Duty, uncovering their ties to conversion therapy, pseudoscience, and policy-driven misinformation. From their influence on anti-LGBTQ legislation to their claims about gender dysphoria treatment, we separate fact from fearmongering.

New Britain Mayor Erin Stewart says she's exploring a run for Governor of Connecticut. New Haven officials will relaunch a plan to improve connectivity on I-91. New York's AG has sued a developer for allegedly building on protected land in the Pine Barrens. New York lawmakers push for a pay raise for restaurant workers. Plus, Democrats are concerned about the White House's freeze of federal grants and loans.

In this JCO Article Insights episode, Ece Cali summarizes findings from the JCO article, "Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study." TRANSCRIPT Ece Cali: Hello and welcome to the JCO Article Insights. I'm your host Ece Cali and today we will be discussing the Journal of Clinical Oncology article the “Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.”  Despite significant advances in non-small cell lung cancer treatment over the past decades, second line treatment options for non-small cell lung cancer without actionable genomic alterations have remained largely unchanged since 2000. Many clinical trials failed to demonstrate improved overall survival compared to docetaxel based regimens. TROPION-Lung01 is a global open label randomized phase 3 trial comparing the efficacy and safety of Dato-DXd to docetaxel in patients with previously treated advanced or metastatic non-small cell lung cancer. Dato-DXd is an antibody drug conjugate targeting TROP2 and delivering deruxtecan, a DNA topoisomerase 1 inhibitor, as its payload. The trial is designed with dual primary endpoints of progression free survival, as assessed by blinded independent central review, and overall survival. The initial PFS results were presented at ESMO in 2023 and this article reports more detailed data and overall survival analysis of the trial.   In the TROPION-Lung01, 299 patients were randomly assigned to receive Dato-DXd and 305 patients to receive docetaxel. Patients were stratified by the presence of actionable genomic alterations, histology, treatment with PD-1/PD-L1 immunotherapy as the last line of therapy, and geographical region. The baseline characteristics of the patient population were overall balanced between the treatment arms. I'd like to highlight a couple of key points here. The median age was 63 years in the Dato-DXd and 64 years in the docetaxel arm. Similar to the many clinical trials in the thoracic oncology field, this is younger than the median age of lung cancer diagnosis in the US, which is around 70. African American and Hispanic patients were underrepresented in this trial with 41% of patients identifying themselves as white and 39% as Asian. The Ddocetaxel arm had a slightly higher percentage of male patients, 69% versus 61%. The majority of the trial population, 73%, had adenocarcinoma. Patients with actionable genomic alterations were included in this trial if they received one or more targeted therapy and platinum based chemotherapy prior to the enrollment. 17% of the trial population had an actionable genomic alteration in this trial.  When it comes to the efficacy results in the full analysis set, the PFS improvement was statistically significant. The median PFS was reported as 4.4 months for the Dato-DXd, and 3.7 months for the docetaxel arm with the hazard ratio of 0.75 and a P value of 0.004. However, after a median follow up of 23 months, the trial did not meet its primary endpoint of overall survival. The median overall survival was 12.9 months for patients treated with Dato-DXd and 11.8 months for patients treated with docetaxel with the hazard ratio of 0.94 and a P value of 0.53. Objective response was a secondary endpoint and the confirmed objective response rate was 26% with Dato-DXd, and 13% with docetaxel.  Now let's take a closer look at some of the subgroup analyses. Exploratory analyses of key subgroups in TROPION-Lung01 demonstrated differences in efficacy based on histology. In the nonsquamous subgroup, Dato-DXd showed a longer progression free survival of 5.5 months compared to 3.6 months with docetaxel with a hazard ratio of 0.84. However, in the squamous subgroup, Dato-DXd performed worse with a progression free survival of 2.8 months compared to 3.9 months with docetaxel corresponding to a hazard ratio of 1.32. A similar trend was observed in the overall survival analyses, though confidence intervals crossed 1 in both histology subsets, in this case, the differences observed were not statistically significant. In the nonsquamous subset, the median overall survival was 14.6 months with Dato-DXd and 12.3 months with docetaxel with a hazard ratio of 0.84. In the squamous subset, both arms had shorter survival compared to the nonsquamous subset. The median overall survival with Dato-DXd was almost two months shorter, so 7.6 months, compared to 9.6 months with docetaxel corresponding to a hazard ratio of 1.32. While these analyses suggest the potential survival benefit for Dato-DXd in nonsquamous subset, this trial was not powered to test this hypothesis hence these analyses remain exploratory. Another subgroup analysis of note was the group with actionable genomic alterations. Patients with actionable genomic alterations achieved a median PFS of 5.7 months with Dato-DXD and 2.6 months with docetaxel corresponding to a hazard ratio of 0.35. Similarly, the median overall survival was longer in patients with actionable genomic alterations by almost six months, with a median overall survival of 15.6 months with Dato-DXd and 9.8 months with docetaxel corresponding to a hazard ratio of 0.65.  Now, let's talk about safety. Grade 3 or higher treatment related adverse events occurred in 26% of patients with Dato-DXd and 42% with docetaxel. The most common adverse event of any grade seen in the Dato-DXd arm were stomatitis seen in 47% of patients, nausea in 34%, and alopecia in 32%. Treatment related interstitial lung disease occurred in 8.8% of patients on Dato-DXd and 4.1% of patients on docetaxel. Of note, grade 5 drug related ILD was more frequent with Dato-DXd. Seven patients on Dato-DXd and one patient on docetaxel died secondary to drug related ILD in this trial.  In summary, TROPION-Lung01 aims to address an unmet need for patients with previously treated non-small cell lung cancer. For this population, the treatment options remain limited with poor survival outcomes. TROPION-Lung01 is a positive trial by design due to clinically modest improvement in PFS. However, the lack of overall survival improvement is disappointing. Exploratory subgroup analyses suggest Dato-DXd may offer survival advantage in specific subsets such as nonsquamous non-small cell lung cancer and patients with actionable genomic alterations. However, these findings require further validation in a prospective trial since TROPION-Lung01 was not designed to address these questions. The data from this trial alone is not sufficient to argue for a change in clinical practice. However, it informs how the future trials using this drug should be tailored. This highlights the importance of studying potential predictive biomarkers earlier in the drug development and incorporating these biomarkers prospectively into the clinical trial designs.  Due to the lack of overall survival benefit in this trial, the biologic license application for accelerated approval of Dato-DXd for patients with previously treated nonsquamous non-small cell lung cancer was voluntarily withdrawn. New BLA was submitted for Dato-DXd for patients with previously treated advanced EGFR positive non-small cell lung cancer. This BLA is based on data from TROPION-Lung05, TROPION-Lung01 and TROPION-PanTumor01. Of note, the results of TROPION-Lung05 trial have been just published in JCO.   This wraps up today's episode. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

As party attempts to complete their exploration of The Earthenwoven Lilac, they stumble upon a discovery most intriguing.Beddlym's Social Hour contains adult language and adult situations. Listener discretion is advised.Credits:DM: BeddlymGrom: Percy SteeleTylylor: Kari DennisMirmulnir: GeorgeLenore: Marc McGrathFind all of our relevant links in our Link Tree.Support us on PatreonUse our affiliate code peaceinthechaos to receive $5.00 off Arkenforge's Master's Toolkit to start creating amazing VTT content.Produced by Peace in the Chaos ProductionsEmail: peaceinthechaosprod@yahoo.com or beddlym.gm@yahoo.comMusic by Monument Studios. Thanks to them for the great music and sound they're creating. Hosted on Acast. See acast.com/privacy for more information.

Hamilton Ulmer is working at the intersection of UI, Exploratory Data Analysis, and SQL at MotherDuck, and he's built a long career in EDA. Hamilton and Tristan dive deep into the history of exploratory data analysis. Even if you spend most of your time below the frontend layer of the stack, it is important to understand the trends in both the practice of data visualization  and the technologies that underlie that practice. For full show notes and to read 6+ years of back issues of the podcast's companion newsletter, head to https://roundup.getdbt.com. The Analytics Engineering Podcast is sponsored by dbt Labs.

To discuss this now, is Fianna Fáil TD Malcolm Byrne and People Before Profit Richard Boyd Barrett.

Send us a textSend us a textHey friends! In this quick update episode, Laurel drops in to share where she and Juniper are in the process of producing the gender exploratory therapy series (spoiler alert…it's a lot more of an in-depth and lengthy process than we anticipated!), and lets everyone know about CMH's winter break.Don't forget that our fundraiser for Advocates for Trans Equality is ongoing! See the links below to direct you straight to where you can purchase these merch items.We hope you have the end to 2024 that you most need, and we will see you in the new year! ✨

Send us a text‼️Content warning for sensitive discussions regarding the LGBTQ community. ⚠️What is Gender Exploratory Therapy, and why is it raising concern amongst therapists and LGBTQ+ advocates? In part 1 of our series, Juniper and Laurel, delve into Therapy First, the organization behind this controversial model. We examine its claims about "exploratory care", and gender-critical approaches, and discuss its implications for trans and gender-diverse communities.

While structured data elements such as patient identifier, medicine name and reaction, are fundamental for adverse event reporting, they may not capture all relevant details. This is where the narrative fields come in, allowing reporters to disclose important contextual information, such as the patient's full clinical course. But how do PV assessors interact with these narratives in spontaneous reports? What needs and challenges do they experience? These and other questions were addressed in an exploratory interview study by UMC researchers Joana Félix and Alem Zekarias.  Tune in to find out:What challenges are PV assessors faced with, when working with narratives? How could automation of certain tasks help streamline narrative analyses in the future?How can reporters craft narratives that effectively document adverse events? Want to know more?Pharmacovigilance assessors' experiences interacting with narrative fields in spontaneous reports: an exploratory interview study – poster presented at the 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics”, 1–5 October 2024 Montreal, Canada.Current Challenges in Pharmacovigilance: Pragmatic Approaches, by The Council for International Organisations of Medical Sciences (CIOMS). See page 133 on the role of narratives in good case management practices. Join the conversation on social mediaFollow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.

In a way, this could be titled “small win season” but the trick is figuring out where to best put your energy. We all have weaknesses but identifying them and investing time in the right place is the catch. Today, we look at different ways to make progress so you're not the same athlete next year as you were this season. Getting better doesn't always have to be hard. Put your energy in the right place. Topics: What is the Midwest? Fun way to break up the off season Athlete rebellion No man's land Create “identifying weeks” Investing time in the right place Performance anxiety Measuring where you are Exploratory training We should know our weaknesses The most crucial part of training Margin for error 10k a day in the pool Sometimes you're just gonna be stronger on one side High cadence vs. lower cadence and the middle ground “I hate Z2 work” Keep what's working ,ditch what's not Deficiencies Go hard on what you regret not going hard on every year Creating a great habit now Everything doesn't have to be hard Small win season   Mike Tarrolly - mike@c26triathlon.com Robbie Bruce - robbie@c26triathlon.com

Today's podcast features Flynn Disney. Flynn is a parkour athlete and human performance coach known for integrating mind, body, and environment in movement training. Flynn combines his history as an athlete with an intensive study of human psychology and experience training animals to provide a unique and insightful perspective on training. All too often, training is thought of on the level of machine-like qualities. Sets, reps, drills, and coaching cues. Rarely do we consider those processes by which children and animals learn, or how the consideration of the total human can change the process by which we coach. Much of this also involves looking at what makes animals and humans both similar and unique, in their movement strength, and abilities. On today's show, Flynn digs into the key differences between animals and humans from a perspective of reflexes and internal wiring, the role of reflexes in training, and examples in plyometric, running, and dynamic “spinal-engine” activities (and the value of “the worm” breakdance move, from an athletic perspective). He talks about the role of attentional networks, and training implications, the impact of risk on our reflex loops in training, and more. Today's episode is brought to you by TeamBuildr's Gym Studio and Athletic Development Games. Use the code “justfly25” for 25% off any Lila Exogen wearable resistance training, including the popular Exogen Calf Sleeves. For this offer, head to: Lilateam.com TeamBuildr is an online software for coaches and trainers. Use the code “JUSTFLY” for a free 30-day trial of the TeamBuildr software. For a Gym Studio 14-day free trial, head to gymstudio.com View more podcast episodes at the podcast homepage. Main Points 9:00- Key differences between human and animal movement, particularly on the level of reflexes 18:00- Attentional aspects of the brain and training implications 24:00- The power of subconscious processes and the relaxation/reflex action in humans 30:00- Playing with varying frequencies in running and sprinting situations 35:00- “The Hero's Journey” of Coaching 50:00- The role and interplace of “Fixed” versus “Exploratory” aspects of training 59:00- Visual tracking and athletic human movements 1:10:00- Risk and reflex arcs in training Quotes “Animal movement is much more constrained by reflexes than human movement; if you take a rabbit and extend their back legs, their front leg will reflexively flex” “We (humans) have many more movement options (than animals)” “Taking small moments of rest (between main sets) is so profound that is so easy to implement; it seems to integrate learning at a deeper level, this cooling down process allowing new neural connections to form” “If you run with a more frequent step, instead of bounds or strides, it's such a different quality” “We're generally less happy when we are in (Default Mode Network) that state, we are more happy when we are task oriented, or sensory oriented” “When a reflex is terminated, it's very satisfying; when you move away from it, it feels dis-satisfying” “If I experience something that is possible, but not completely unimaginable, I will get a surge of energy” About Flynn Disney Flynn Disney is a professional parkour athlete and coach, known for his innovative approach to movement and skill development. Based in London, his mastery of parkour fundamentals, coupled with a deep understanding of biomechanics, has made him a sought-after coach in the movement training community. As a coach, Flynn emphasizes an approach the integrates mind and body, helping athletes of all levels break through physical and psychological barriers. Flynn also contributes to the sport through workshops and content that promote parkour as a tool for developing adaptable and well-rounded athletes.

WWE RAW was in Rip City, so what will we have to rip on this show? -What kind of car does CM Punk drive? -Where's the valet? -I'm prepared to die -Don't call him Butch. Seriously. -Woods doesn't want any help -Miz is no monster -Iron Hart vs Chris Kattan -Shannon Sharpe angle -Finn played match maker -Why is Breakker doing a good guy promo? -Walk him like a dog -Bianca Stamp -The end of the New Day? -What's next for the Wyatt Sicks? -Braun vs Bronson needs 10 ambulances -Monster's Ball? -Sami tries to wedge Gunther and Kaiser -Bianca lost? -Lucky Wade -What's Jey waiting for? Subscribe on patreon.com/LingusMafia for ad-free and video versions of the show, exclusive PPV/PLE reviews and bonus shows including every Wrestlemania, SummerSlam, Royal Rumble and Saturday Night's Main Event ever. Stay connected: All our social media (@LingusMafia) links can be found here: https://linktr.ee/lingusmafia Download the PrizePicks app today and use code CCN and get $50 instantly when you play $5! That's code CCN on PrizePicks to get $50 instantly when you play $5! You don't even need to win to receive the $50 bonus, it's guaranteed! "PrizePicks. Run Your Game!"

In part one of Red Eye Radio with Gary McNamara and Eric Harley, sports personalities weigh in on current politics: Stephen A. Smith is now full #kaMAGA after he slams Harris for not doing a press conference, and Chris "Mad Dog" Russo goes off on a Trump tirade for the way he treated President Biden; Harris will suggest price controls for food in an upcoming speech; The late great economist Milton Friendman on inflation; Harris reportedly wants to distance the campaign from Bidenomics; Andrew McCarthy says Judge Merchan will sentence Trump to jail on September 10th; We need an explanation on why former Congresswoman Tulsi Gabbard is on a no fly list; Clueless Harris supporters are interviewed;  For more talk on the issues that matter to you, listen on radio stations across America Monday-Friday 12am-5am CT (1am-6am ET and 10pm-3am PT), download the RED EYE RADIO SHOW app, asking your smart speaker, or listening at RedEyeRadioShow.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome back to our special Back to School series, where we're revisiting some of the most popular and impactful episodes to help you gear up for the new school year. These episodes have resonated with so many educators and parents, and we're excited to share them with you again. Let's dive into the first one! As we head back into the classroom, understanding the developmental stages of play is crucial for supporting our young autistic students. In this episode, we explore the concept of "exploratory play"—a stage where children might dump toys, throw objects, or mouth everything. Instead of seeing these actions as a lack of play skills, we'll discover how they are part of a natural developmental process. Join me as I discuss how "put in" and "take out" activities can guide children in this exploratory stage toward more functional play. Let's get started! Topics Discussed: Exploratory play Put in activities Take out activities Suggestions for types of activities to use Next steps to expand   Links Mentioned In This Episode About Visual Supports:  Take Out The Toys Booklet Put In & Take Out Toys List On Amazon Themed Play Visual Supports Podcast Episode About Exploratory Play Blog Post About Exploratory Play The Hanen Centre   Other Links You May Be Interested In: Autism Little Learners on Instagram Autism Little Learners on Facebook You can also join my free Visual Supports Facebook Group to “hang out” with like-minded educators and parents who want to take action and implement visuals at home or school. Be sure to subscribe to The Autism Little Learners Podcast so you don't miss future episodes.  Plus, leave a rating & review on iTunes….this will help other educators and parents find this podcast!  CLICK HERE to leave a review on iTunes, then scroll down to “ratings and reviews” and click “write a review”.  THANK YOU!

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss the survival analysis of the PAOLA1 trial. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field.   Highlights: Bevacizumab plus olaparib has reported to increase PFS and OS in advanced stage III-IV, newly diagnosed, high grade serous and endometrioid HRD positive ovarian cancer in the maintenance setting  Exploratory analysis suggest that the advantage is particularly high in low risk patients (stage III withour residual tumor at primary surgery) where  a 5-year OS more  than 90% has been reported suggesting some of these patients may be cured In the HRp population the combination of olaparib-bevacizumab did non increase PFS and OS in comparison to bevacizumab alone The toxicity profile of the combination is in line with what expected with the single drugs

In this podcast, JPEN Editor-in-Chief Dr. Kenneth Christopher interviews Kym Wittholz, a clinical lead critical care dietitian and PhD candidate whose specific interest is in critical care nutrition at The Royal Melbourne Hospital in Melbourne, Australia, and the first author of the research article “Plasma beta-hydroxy-beta-methylbutyrate availability after enteral administration during critical illness after trauma: An Exploratory study”. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US May 2024

The Party defends Fait and his thesis. Mori goes see themselves, Todd gets horny, Fait breaks, Eldrin becomes what he fears most, Fait breaks some barriers, and Baba is out of his locale.Support the Party and get some loot in return: https://www.patreon.com/gmdlcastJoin our Discord: https://discord.gg/RsMGSP2DhCWatch our stream: https://www.twitch.tv/gmdlcast Spread the word: https://gmdlcast.com/listenFind us: https://bsky.app/profile/gmdlcast.bsky.socialhttps://www.threads.net/@gmdlcast

Seth and Sean react to Adam Schefter reporting that Russell Wilson had an "exploratory" meeting with the Giants, and dive into the worst Quarterback trades of all time.

Support the show to get full episodes and join the Discord community. You may know my guest as the co-founder of Neuromatch, the excellent online computational neuroscience academy, or as the creator of the Brian spiking neural network simulator, which is freely available. I know him as a spiking neural network practitioner extraordinaire. Dan Goodman runs the Neural Reckoning Group at Imperial College London, where they use spiking neural networks to figure out how biological and artificial brains reckon, or compute. All of the current AI we use to do all the impressive things we do, essentially all of it, is built on artificial neural networks. Notice the word "neural" there. That word is meant to communicate that these artificial networks do stuff the way our brains do stuff. And indeed, if you take a few steps back, spin around 10 times, take a few shots of whiskey, and squint hard enough, there is a passing resemblance. One thing you'll probably still notice, in your drunken stupor, is that, among the thousand ways ANNs differ from brains, is that they don't use action potentials, or spikes. From the perspective of neuroscience, that can seem mighty curious. Because, for decades now, neuroscience has focused on spikes as the things that make our cognition tick. We count them and compare them in different conditions, and generally put a lot of stock in their usefulness in brains. So what does it mean that modern neural networks disregard spiking altogether? Maybe spiking really isn't important to process and transmit information as well as our brains do. Or maybe spiking is one among many ways for intelligent systems to function well. Dan shares some of what he's learned and how he thinks about spiking and SNNs and a host of other topics. Neural Reckoning Group. Twitter: @neuralreckoning. Related papers Neural heterogeneity promotes robust learning. Dynamics of specialization in neural modules under resource constraints. Multimodal units fuse-then-accumulate evidence across channels. Visualizing a joint future of neuroscience and neuromorphic engineering. 0:00 - Intro 3:47 - Why spiking neural networks, and a mathematical background 13:16 - Efficiency 17:36 - Machine learning for neuroscience 19:38 - Why not jump ship from SNNs? 23:35 - Hard and easy tasks 29:20 - How brains and nets learn 32:50 - Exploratory vs. theory-driven science 37:32 - Static vs. dynamic 39:06 - Heterogeneity 46:01 - Unifying principles vs. a hodgepodge 50:37 - Sparsity 58:05 - Specialization and modularity 1:00:51 - Naturalistic experiments 1:03:41 - Projects for SNN research 1:05:09 - The right level of abstraction 1:07:58 - Obstacles to progress 1:12:30 - Levels of explanation 1:14:51 - What has AI taught neuroscience? 1:22:06 - How has neuroscience helped AI?

In this podcast, I take an in-depth look at our current exploratory design process.

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: The BEST form of exercise to directly combat the aging process is strength training! (2:13) Fyre Fest's Billy McFarland is out of prison and back at it! (9:00) Alec Baldwin is tone-deaf. (11:46) Selective outrage and Kanye West. (13:15) An example of when you don't think things out. (25:34) Food hacks with Butcher Box. (32:17) The food industry is a brutal business. (33:21) Gas-powered all day! (39:03) NYC employees were reinstated for not getting vaccinated. (40:50) Is Jake Paul the future of boxing? (45:03) Technology is cool. (46:52) PRx's new feature and Mind Pump's ideal gym. (49:47) The potential anti-cancer effects of creatine. (54:20) #ListenerLive question #1 - How do you lose fat without losing weight? (57:51) #ListenerLive question #2 - If I keep lifting light instead of lifting to my max every workout, does this help in the long term in preventing those knots I had? (1:13:07) #ListenerLive question #3 - How do you guys recommend incorporating running with your weightlifting programs? (1:25:07) #ListenerLive question #4 - What is the best way to lift weights as a boxer? (1:33:13) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com MIND PUMP LIVE Q&A W/ MAX LUGAVERE Visit Butcher Box for this month's exclusive Mind Pump offer! Visit PRx Performance for an exclusive offer for Mind Pump listeners! November Promotion: MAPS OCR or MAPS Cardio HALF OFF! **Promo code NOVEMBER50 at checkout** Dr. Andy Galpin Post on Strength Training Association of Grip Strength With Risk of All-Cause Mortality, Cardiovascular Diseases, and Cancer in Community-Dwelling Populations: A Meta-analysis of Prospective Cohort Studies Billy McFarland, Fresh Out Of Prison After The Fyre Fest Fiasco, May Be Trying To Launch Another Festival For Some Reason ALEC BALDWIN GETS DRAGGED FOR TONE-DEAF POST ABOUT SHOOTING A WOMAN A YEAR AGO Billionaire No More: Kanye West's Antisemitism Obliterates His Net Worth As Adidas Cuts Ties Mississippi daycare workers fired after screaming at children in Halloween mask LUNA Mexican Kitchen VISCONTI'S RISTORANTE Biden Infrastructure Bill Mandates Vehicle Kill Switches By 2026 Court Orders New York City To Reinstate Unvaccinated Employees Dyson is developing robots that do household chores Exploratory studies of the potential anti-cancer effects of creatine Visit LivON Labs for an exclusive offer for Mind Pump listeners! MAPS Strong MAPS Powerlift Mind Pump #1932: Lifting Heavy Vs. Lifting Light MAPS Symmetry MAPS Prime Webinar Mind Pump #1925: How To Build A Great Physique In 15 Minutes A Day MAPS 15 Minutes   MAPS Fitness Performance   Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Dr. Andy Galpin (@drandygalpin) Instagram Jake Paul (@jakepaul) Instagram